HBME1

HBME1

An antibody which reacts with a mesothelial cell membrane antigen located in microvilli. Whilst HBME1 has a low specificity in differentiating mesotheliomas from adenocarcinomas, it is often positive in papillary carcinoma of the thyroid.
References in periodicals archive ?
Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining.
Abbreviations: CITED1, CREB-binding protein/ p300-interacting transactivator with Asp/Glu-rich C-terminal domain 1; CK19, cytokeratin 19; FA, follicular adenoma; FC, follicular carcinoma; FTUMP, follicular tumor of undetermined malignant potential; FVPTC, follicular variant of papillary thyroid carcinoma; Galectin-3, galactoside-binding lectin soluble 3; HBME1, Hector Battifora mesothelial 1; IMP3, insulin-like growth factor II messenger RNA binding protein 3; PTC, papillary thyroid carcinoma.
Contribution of immunocytochemical stainings for galectin-3, CD44, and HBME1 to fine-needle aspiration cytology diagnosis of papillary thyroid carcinoma.
Immunohisto-chemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining.
Reduced HBME1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes.
Cytokeratin 19 expression was cytoplasmic, CITED1 expression was nuclear and cytoplasmic, and HBME1 expression was membranous, apical, and cytoplasmic (Figure 2, A through D).
Only 4 follicular adenomas (of 26) and 1 goiter (of 27) were positive for HBME1 on the TMA (5 of 80), whereas the corresponding whole section immunohistochemistry showed positive expression in 9 cases (1 of 8 FTCs, 4 of 26 adenomas, and 4 of 27 goiters).